The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•21 April 2026•

1 min read

Smith+Nephew Gains on Positive 5-Year Data for AGILI-C Cartilage Implant

Key Facts

15-year data for CARTIHEAL AGILI-C implant showed superior pain relief and functional gains compared to surgical standard of care.

about 1 month ago

Version History

Version 1about 1 month ago

What changed: The story was updated to include specific clinical metrics (KOOS scores) and the exact effective date for the new reimbursement code on January 1, 2027.

Smith+Nephew has released positive long-term clinical data for its CARTIHEAL AGILI-C implant, demonstrating higher Knee Injury and Osteoarthritis Outcome Scores (KOOS) over a 60-month period compared to traditional surgical standards. The study revealed that the implant delivered twice the reduction in pain scores alongside significant functional gains for patients. Furthermore, the Category I CPT code for the device is now confirmed to become effective on January 1, 2027, a move expected to streamline medical reimbursement and accelerate commercial adoption. These findings bolster investor confidence in the company's orthopedic portfolio, particularly as it addresses the treatment gap prior to total joint replacement. This clinical validation, combined with a clear regulatory timeline, is viewed as a bullish driver for the company's stock.